DOP2002000494A - Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesión celular - Google Patents

Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesión celular

Info

Publication number
DOP2002000494A
DOP2002000494A DO2002000494A DO2002000494A DOP2002000494A DO P2002000494 A DOP2002000494 A DO P2002000494A DO 2002000494 A DO2002000494 A DO 2002000494A DO 2002000494 A DO2002000494 A DO 2002000494A DO P2002000494 A DOP2002000494 A DO P2002000494A
Authority
DO
Dominican Republic
Prior art keywords
join
human antibodies
neutralizing activity
cellular adhesion
cellular
Prior art date
Application number
DO2002000494A
Other languages
English (en)
Spanish (es)
Inventor
Toshihiko Tekeuchi
Stringfellow Nathalie Dubois
John E Murphy
Julie Rinkenberger
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of DOP2002000494A publication Critical patent/DOP2002000494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DO2002000494A 2001-10-18 2002-10-17 Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesión celular DOP2002000494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02

Publications (1)

Publication Number Publication Date
DOP2002000494A true DOP2002000494A (es) 2004-05-31

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000494A DOP2002000494A (es) 2001-10-18 2002-10-17 Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesión celular

Country Status (18)

Country Link
US (2) US7462696B2 (https=)
EP (1) EP1438339A4 (https=)
JP (2) JP2005528884A (https=)
KR (1) KR20050037478A (https=)
CN (1) CN1606569A (https=)
AR (1) AR036833A1 (https=)
BR (1) BR0213968A (https=)
CA (1) CA2463943A1 (https=)
CO (1) CO5370684A1 (https=)
DO (1) DOP2002000494A (https=)
HU (1) HUP0600335A2 (https=)
IL (1) IL161411A0 (https=)
MX (1) MXPA04003508A (https=)
PE (1) PE20030473A1 (https=)
PL (1) PL374304A1 (https=)
RU (1) RU2317998C2 (https=)
UY (1) UY27499A1 (https=)
WO (1) WO2003033674A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN106662578B (zh) * 2014-04-03 2021-11-12 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
ES2296412T3 (es) * 1998-10-23 2008-04-16 Institute Of Virology Gen y proteina mn.
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
US20030077277A1 (en) 2003-04-24
HUP0600335A2 (en) 2006-08-28
PE20030473A1 (es) 2003-06-26
JP2010260845A (ja) 2010-11-18
CA2463943A1 (en) 2003-04-24
PL374304A1 (en) 2005-10-03
US20100240100A1 (en) 2010-09-23
UY27499A1 (es) 2003-05-30
WO2003033674A3 (en) 2003-08-21
KR20050037478A (ko) 2005-04-22
MXPA04003508A (es) 2004-07-22
IL161411A0 (en) 2004-09-27
RU2317998C2 (ru) 2008-02-27
CN1606569A (zh) 2005-04-13
CO5370684A1 (es) 2004-02-27
EP1438339A2 (en) 2004-07-21
RU2004115112A (ru) 2005-04-27
WO2003033674A2 (en) 2003-04-24
EP1438339A4 (en) 2008-08-27
AR036833A1 (es) 2004-10-06
BR0213968A (pt) 2005-05-10
JP2005528884A (ja) 2005-09-29
US7462696B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
DOP2002000494A (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesión celular
DK1432735T3 (da) Antagonistiske humane anti-htnfsf13b-antistoffer
BR0100925B1 (pt) conjunto de painéis e elementos de junção.
EP1404702A4 (en) SEPARATE HUMAN PROTEINS
EP1386155A4 (en) THERAPEUTIC AND DIAGNOSTIC USE OF ANTIBODY SPECIFICITY PROFILES
DE60136152D1 (de) Kontext und Aufenthaltsort-kennende zellulare Telefone und Verfahren
DE60231726D1 (de) Doppelkolben-einphasen-probeentnahmemechanismus und -verfahren
IL209010A0 (en) Use of tnfalpha antibodies and another drug
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
CY2012002I2 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
EP1512396A4 (en) HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
EP1506286A4 (en) NEUTRALIZATION OF A HUMAN ANTI-IGFR ANTIBODY
DE60227301D1 (de) Strukturen von anschlusselementen und anzuschliessende komponente
EP1394232A4 (en) HYDROGEN AND OLEOPHOBIC AGENTS
DE60226997D1 (de) Martensitischer rostfreier stahl und herstellungsverfahren dafür
DE60234323D1 (de) Künstliche dermis und herstellungsverfahren dafür
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
EP1383888A4 (en) SEPARATE HUMAN PROTEINS
DE60208700D1 (de) Schälgerät und zugehörige verfahren
BR0117163B1 (pt) método e equipamento para a preparação de hidrazodicarbonamida utilizando uréia como material de partida.
FI20031472A0 (fi) Menetelmä verkkosuuntaajan yhteydessä ja verkkosuuntaaja
IS2724B (is) 5-hluta heteróhringir, framleiðsla og notkun þeirra sem lyfja
DE60234169D1 (de) Ferritischer wärmebeständiger stahl und herstellungsverfahren dafür
DE60120727D1 (de) Angestauchte rorhverbindungsmanschette und matrize
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine